PainReform (PRFX)
NASDAQ:PRFX
Top Page
PainReform
(NASDAQ:PRFX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.50
▲(212.50% Upside)
Action:ReiteratedDate:03/28/26
PRFX scores low primarily due to extremely weak fundamentals (minimal revenue, sizable losses, and continued cash burn). Technicals add further pressure given the strong downtrend below key moving averages, despite oversold readings. Valuation is also constrained by negative earnings and no indicated dividend support.
Positive Factors
Low leverage
Very low recorded debt reduces solvency risk and gives the company more time to develop its dual platforms without immediate refinancing pressure. Low leverage preserves financial optionality, limiting bankruptcy probability while the business pursues commercialization.
Negative Factors
Minimal revenue & losses
The company remains far from break-even with negligible product revenue and large operating losses. Persistent negative margins and limited commercial sales mean PRF will need successful product commercialization or sustained financing to reach self-sustaining cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low recorded debt reduces solvency risk and gives the company more time to develop its dual platforms without immediate refinancing pressure. Low leverage preserves financial optionality, limiting bankruptcy probability while the business pursues commercialization.
Read all positive factors
PainReform (PRFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.14M
Dividend YieldN/A
Average Volume (3M)186.11K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.04
Shares Outstanding844,372
10 Day Avg. Volume213,091
30 Day Avg. Volume186,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)122.35
P/FCF Ratio-0.53
Enterprise Value/Market Cap-1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-176.4
Revenue Forecast (FY)$10.31M
PainReform Business Overview & Revenue Model
Company Description
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-bas...
PainReform Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 17.00K | 0.00 | 0.00 | 86.00K | 0.00 |
| Gross Profit | 0.00 | -827.00K | -16.00K | -15.00K | 71.00K | ― |
| EBITDA | -3.94M | -4.21M | -14.55M | -9.57M | -8.76M | -7.20M |
| Net Income | -4.09M | -4.84M | -14.59M | -9.34M | -8.79M | -7.25M |
Balance Sheet | ||||||
| Total Assets | 11.16M | 12.00M | 4.53M | 9.93M | 12.33M | 19.07M |
| Cash, Cash Equivalents and Short-Term Investments | 3.48M | 4.17M | 4.26M | 8.03M | 4.10M | 16.54M |
| Total Debt | 56.00K | 21.00K | 45.00K | 86.00K | 0.00 | 0.00 |
| Total Liabilities | 2.72M | 2.71M | 2.70M | 2.69M | 1.31M | 991.00K |
| Stockholders Equity | 8.44M | 8.54M | 1.82M | 7.24M | 11.02M | 18.08M |
Cash Flow | ||||||
| Free Cash Flow | -5.96M | -3.96M | -12.63M | -6.69M | -6.46M | -6.60M |
| Operating Cash Flow | -5.96M | -3.96M | -12.62M | -6.68M | -6.46M | -6.55M |
| Investing Cash Flow | -51.00K | -982.00K | -13.00K | 5.99M | -6.01M | -50.00K |
| Financing Cash Flow | 6.70M | 3.82M | 8.86M | 4.62M | 0.00 | 7.48M |
PainReform Technical Analysis
Neutral
0.80
Price Trends
2.86
Negative
3.63
Negative
5.33
Negative
Market Momentum
-0.22
Negative
51.01
Neutral
47.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRFX, the sentiment is Neutral. The current price of 0.8 is below the 20-day moving average (MA) of 2.37, below the 50-day MA of 2.86, and below the 200-day MA of 5.33, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 51.01 is Neutral, neither overbought nor oversold. The STOCH value of 47.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRFX.
PainReform Risk Analysis
PainReform disclosed 46 risk factors in its most recent earnings report. PainReform reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PainReform Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.22M | -0.42 | ― | ― | ― | ― | |
45 Neutral | $3.07M | ― | -43.00% | ― | -26.92% | 69.90% | |
42 Neutral | $2.14M | -0.43 | ― | ― | ― | ― | |
40 Underperform | $11.59M | -1.59 | -63.82% | ― | ― | ― | |
| ― | $4.17M | -0.25 | -9999.00% | ― | ― | 79.31% |
* Healthcare Sector Average
PRFX
PainReform
2.53
-6.21
-71.06%
CPHI
China Pharma Holdings
0.61
-0.74
-54.74%
RDHL
RedHill Biopharma
0.83
-1.51
-64.57%
COSM
Cosmos Holdings
0.31
-0.02
-6.93%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.75
-9.43
-92.67%
PainReform Corporate Events
PRF Technologies Posts 2025 Results as LayerBio and DeepSolar Deals Drive Dual-Platform Pivot
Mar 27, 2026
On March 27, 2026, PRF Technologies issued a year-end 2025 update detailing a strategic pivot into dual platforms in healthcare and renewable-energy analytics. The company reported a sharply reduced annual net loss of about $4.8 million versus $14...
PRF Technologies Taps Blade Ranger to Drive Utility-Scale DeepSolar Deals
Mar 17, 2026
On March 16, 2026, Israel-based PRF Technologies entered a commercial collaboration agreement with Blade Ranger Ltd. to drive large-scale adoption of its DeepSolar AI analytics platform across utility-scale solar portfolios. Under the deal, Blade ...
PRF Technologies Reshapes Top Leadership With New Interim CEO and Permanent CFO
Mar 3, 2026
PRF Technologies Ltd., formerly known as PainReform, is an Israel-based healthcare company focused on developing technologies and products in the medical and biopharmaceutical space. The company targets global markets through its innovation-driven...
PRF Technologies’ DeepSolar Lands First Commercial Due Diligence Deal with EDF in Israel
Feb 18, 2026
On February 18, 2026, PRF Technologies announced that its DeepSolar unit signed its first commercial technical due diligence engagement with a subsidiary of EDF Group’s Israeli renewable-energy arm, covering an operational utility-scale sola...
PRF Technologies Secures 71 MW DeepSolar SaaS Deployment in Romania
Feb 11, 2026
PRF Technologies, via its DeepSolar AI-driven solar analytics unit, has signed a commercial software-as-a-service agreement with Shikun Binui Energy to deploy DeepSolar at the 71 megawatt Satu Mare utility-scale photovoltaic plant in Romania, as ...
PRF Technologies Announces 1-for-5 Reverse Share Split Effective February 6, 2026
Feb 3, 2026
On February 3, 2026, PRF Technologies Ltd. announced it will implement a 1-for-5 reverse share split of its ordinary shares, effective for trading on the Nasdaq Capital Market starting Friday, February 6, 2026. The move will consolidate every five...
PRF Technologies Files First Patent for AI-Driven Solar Micro-Climate Forecasting
Jan 20, 2026
On January 20, 2026, PRF Technologies announced it had filed its first patent application for proprietary micro-climate modeling methods designed to significantly enhance the accuracy of power production forecasts at individual solar plants. The f...
PainReform Rebrands as PRF Technologies to Reflect Expansion into Healthcare and AI-Driven Energy
Jan 15, 2026
On January 15, 2026, PainReform Ltd. announced it had changed its corporate name to PRF Technologies Ltd., following shareholder approval at the company’s January 6, 2026 annual general meeting, in a move designed to signal its evolution bey...
PainReform Reports Positive Phase I Safety Data for OcuRing-K Ocular Drug Platform
Jan 12, 2026
On January 12, 2026, PainReform and its majority-owned subsidiary LayerBio reported that their OcuRing™-K drop-less, sustained-release intraocular drug delivery platform for cataract surgery demonstrated a favorable safety profile in a serie...
PainReform Files Pro Forma Financials Following Majority Acquisition of LayerBio
Jan 7, 2026
On January 7, 2026, PainReform Ltd. filed a Form 6-K in the United States providing updated financial disclosure related to its acquisition of LayerBio Inc., a transaction first announced in July 2025 and completed on August 13, 2025, in which Pai...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.